Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD
Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...
21 Apr 23min
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...
14 Apr 18min
Podcast: Best Practices For Patient Identification
Stay up to date on MASH and MASLD with expert insights from nurse practitioners Sarah Dawkins of Duke University Medical Center and Edith Johannes of UCLA Health. This episode focuses on best practice...
7 Apr 17min
Podcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
In this episode of RhAPPcast, host Amanda Mixon, PA-C, is joined by Christina Hanson, NP, to explore the growing intersection between rheumatology and gastroenterology, focusing on shared immune pathw...
31 Mars 23min
FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?
Thank you to Johnson & Johnson for the support on this FAQ Video Module.In this FAQ video module, Tedra Gray, a gastroenterology nurse practitioner at Sinai Chicago, breaks down the key differences be...
24 Mars 3min
Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data
Thank you to Johnson & Johnson for the support on this Medication Review Video Module. In this medication review video module, Kimberly Orleck, PA-C, reviews the long-term efficacy and safety of gusel...
17 Mars 5min
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
In this podcast, host Amanda Mixon, PA-C, leads a 2026 Fireside Chat exploring the intersection of rheumatology and gastroenterology. Joined by Kim Orleck, PA-C (GI APP), and Wendy Simmons, PA-C (Rheu...
10 Mars 36min
Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results
Thank you to AbbVie for the support on this Journal Club Review Video Module.In this journal club review, Kimberly Orleck, PA-C, discusses the long-term efficacy and safety of risankizumab, an IL-23 p...
24 Feb 7min
